COLD AGGLUTININ DISEASE
Clinical trials for COLD AGGLUTININ DISEASE explained in plain language.
Never miss a new study
Get alerted when new COLD AGGLUTININ DISEASE trials appear
Sign up with your email to follow new studies for COLD AGGLUTININ DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cell therapy offers hope for tough anemia cases
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia that hasn't improved after at least three prior treatments. The therapy uses specially engineered immune cells to target and destroy the faulty cells causing the anemia. The …
Matched conditions: COLD AGGLUTININ DISEASE
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental cell therapy takes on tough blood disorder
Disease control Not yet recruitingThis early-phase trial tests a new cell therapy called YTS109 in 13 adults with autoimmune hemolytic anemia that has not responded to at least three prior treatments. The therapy uses specially engineered immune cells to target and control the disease. The main goals are to check…
Matched conditions: COLD AGGLUTININ DISEASE
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
CAR-T therapy takes on tough blood disorder in early trial
Disease control Not yet recruitingThis early-stage trial tests a new CAR-T cell therapy called inaticabtagene autoleucel for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. The study will enroll 12 adults and primarily check for safety and the right dose.…
Matched conditions: COLD AGGLUTININ DISEASE
Phase: PHASE1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for rare blood disorder: linprixel trial launches
Disease control Not yet recruitingThis phase 2 trial tests linprixel, a daily pill, in 22 adults with relapsed or refractory autoimmune hemolytic anemia (AIHA). The study aims to see if the drug can improve red blood cell counts after 12 weeks. Participants start at 40mg daily, with possible dose increases if nee…
Matched conditions: COLD AGGLUTININ DISEASE
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 26, 2026 12:46 UTC